GlassScriptPhysician profile
Jamil Syed
NPI 1417485236
$6,147.50
in general payments reported to CMS, 2019-2025
12 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $336 · 2023: $3,895 · 2024: $809 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,299 · Travel and Lodging: $2,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.24 |
| Travel and Lodging | $2,511.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,182.49 | 2022-2025 | Spaceoar Vue System - 10ml, Lumenis Pulse 120h, Lithovue |
| Angiodynamics, INC. | $1,469.77 | 2022-2025 | Nanoknife |
| Procept Biorobotics Corporation | $437.40 | 2024-2025 | Aquabeam System |
| Coloplast Corp | $368.59 | 2022-2025 | Speedicath |
| C. R. Bard, INC. & Subsidiaries | $180.34 | 2024 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Bioprotect Medical, INC. | $155.11 | 2025 | Bioprotect Balloon Implant System |
| Seagen INC. | $125.00 | 2022 | |
| Koelis INC. | $116.97 | 2025 | |
| Edap Technomed INC | $48.42 | 2025 | |
| Abbvie INC. | $24.46 | 2023 | Botox |
| Becton, Dickinson and Company | $21.91 | 2024 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Medical Device Business Services, INC. | $17.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.